ALK and cancer: Treatment strategies of lung cancers have expanded greatly in recent years with the development of targeting therapy in cancer-specific oncogenic driver mutations, such as the epidermal growth factor receptor (EGFR), the anaplastic lymphoma kinase (ALK) and ROS1 rearrangements.